Chest ACCP Education Calendar
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pass, H. I.
Right arrow Articles by Carbone, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pass, H. I.
Right arrow Articles by Carbone, M.
(Chest. 1999;116:455S-460S.)
© 1999 American College of Chest Physicians

Emerging Translational Therapies for Mesothelioma*

Harvey I. Pass, MD, FCCP; Bruce W. Robinson, MD; Joseph R. Testa, PhD and Michele Carbone, MD, PhD

* From the Karmanos Cancer Institute, Wayne State University, Detroit, MI (Dr. Pass); University of Western Australia, Perth, Australia (Dr. Robinson); Fox Chase Cancer Center, Philadelphia, PA (Dr. Testa); and Cardinal Bernardin Cancer Center, Loyola University, Maywood, IL (Dr. Carbone).

Correspondence to: Harvey I. Pass, MD, FCCP, Harper Hospital, 3990 John R, Suite 2102, Detroit, MI 48201;

Malignant pleural mesothelioma remains a therapeutic and diagnostic problem. Translational mechanisms for treatment of the disease are emerging from newly learned characteristics of the tumor on a molecular, cellular, and extracellular basis. Although slow to reach the clinical arena, these potential strategies do show proof of principle in the in vitro and in vivo settings, and some, including adenoviral molecular chemotherapy, have completed phase I testing. This review describes the rationale and status of these newer treatment ideas.




This article has been cited by other articles:


Home page
 Ann. Thorac. Surg.Home page
R. Bueno, J. Reblando, J. Glickman, M. T. Jaklitsch, J. M. Lukanich, and D. J. Sugarbaker
Pleural Biopsy: A Reliable Method for Determining the Diagnosis But Not Subtype in Mesothelioma
Ann. Thorac. Surg., November 1, 2004; 78(5): 1774 - 1776.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
W. R. Smythe, I. Mohuiddin, M. Ozveran, and X. X. Cao
Antisense therapy for malignant mesothelioma with oligonucleotides targeting the bcl-xl gene product
J. Thorac. Cardiovasc. Surg., June 1, 2002; 123(6): 1191 - 1198.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
X. X. Cao, I. Mohuiddin, F. Ece, D. J. McConkey, and W. R. Smythe
Histone Deacetylase Inhibitor Downregulation of bcl-xl Gene Expression Leads to Apoptotic Cell Death in Mesothelioma
Am. J. Respir. Cell Mol. Biol., November 1, 2001; 25(5): 562 - 568.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Marrogi, H. I. Pass, M. Khan, L. J. Metheny-Barlow, C. C. Harris, and B. I. Gerwin
Human Mesothelioma Samples Overexpress Both Cyclooxygenase-2 (COX-2) and Inducible Nitric Oxide Synthase (NOS2): In Vitro Antiproliferative Effects of a COX-2 Inhibitor
Cancer Res., July 1, 2000; 60(14): 3696 - 3700.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the American College of Chest Physicians.